Ricerc@Sapienza

Emicizumab has been approved in several countries for regular prophylaxis in patients with congenital haemophilia A and FVIII inhibitors because it substantially reduces their bleeding risk and improves quality of life. However, although significantly less frequent, some breakthrough bleeds may still occur while on emicizumab, requiring treatment with bypassing or other haemostatic agents. Thrombotic complications have been reported with the associated use of activated prothrombin complex concentrates.

In August 2018, Ockerman et al. [1] published a systematic review about local hemostatic measures after tooth removal in patients on antithrombotic treatment, excluding from the anal- ysis some articles whose outcome was not the number of bleeding events [2–6]. In that study, however, post-operative bleeding was not defined, and therefore, it can be supposed that, since bleeding is a natural event after tooth extractions, Ockerman et al.